In yesterday’s Wall Street session, Ocular Therapeutix Inc. (NASDAQ:OCUL) shares traded at $2.81, up 0.36% from the previous session.
As of this writing, 7 analysts cover Ocular Therapeutix Inc. (NASDAQ:OCUL). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $25.00 and a low of $5.00, we find $14.00. Given the previous closing price of $2.80, this indicates a potential upside of 400.0 percent. OCUL stock price is now -9.68% away from the 50-day moving average and -31.82% away from the 200-day moving average. The market capitalization of the company currently stands at $215.61M.
There are 1 analysts who have given it a hold rating, whereas 6 have given it a buy rating. Brokers who have rated the stock have averaged $13.29 as their price target over the next twelve months.
On August 10, 2021, H.C. Wainwright Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $17, while ‘Berenberg’ rates the stock as ‘Buy’.
In other news, SUMMER ROAD LLC, 10% Owner bought 7,328 shares of the company’s stock on Nov 07. The stock was bought for $25,648 at an average price of $3.50. Upon completion of the transaction, the 10% Owner now directly owns 6,122,089 shares in the company, valued at $17.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 11, 10% Owner SUMMER ROAD LLC bought 10,000 shares of the business’s stock. A total of $38,993 was incurred on buying the stock at an average price of $3.90. This leaves the insider owning 6,114,761 shares of the company worth $17.18 million. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OCUL stock. A new stake in Ocular Therapeutix Inc. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $1,494,000. IKARIAN CAPITAL, LLC invested $745,000 in shares of OCUL during the first quarter. In the first quarter, TWO SIGMA INVESTMENTS, LP acquired a new stake in Ocular Therapeutix Inc. valued at approximately $556,000. GRAHAM CAPITAL MANAGEMENT, L.P. acquired a new stake in OCUL for approximately $534,000. ERGOTELES LLC purchased a new stake in OCUL valued at around $335,000 in the second quarter. In total, there are 174 active investors with 56.60% ownership of the company’s stock.
Friday morning saw Ocular Therapeutix Inc. (NASDAQ: OCUL) opened at $2.6600. During the past 12 months, Ocular Therapeutix Inc. has had a low of $2.57 and a high of $7.38. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.00, and a quick ratio of 4.90. The fifty day moving average price for OCUL is $3.0900 and a two-hundred day moving average price translates $4.1097 for the stock.
The latest earnings results from Ocular Therapeutix Inc. (NASDAQ: OCUL) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.25, missing analysts’ expectations of -$0.23 by -0.02. This compares to $0.03 EPS in the same period last year. The company reported revenue of $11.96 million for the quarter, compared to $12.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.55 percent. For the current quarter, analysts expect OCUL to generate $14.27M in revenue.
Ocular Therapeutix Inc.(OCUL) Company Profile
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.